Cassandra J Vandenberg 37th Lorne Cancer Conference 2025

Abstracts this author is presenting:

• Preclinical evaluation of farletuzumab ecteribulin (FZEC) and MORAb-109, antibody-drug conjugates (ADCs) targeting folate receptor alpha and mesothelin, in high-risk gynaecological cancers. — Session 6: Hormone Regulated Cancers